4821-88-9

Usage

Uses

Used in Pharmaceutical Industry:
6,7-Dimethoxyphthalazin-1(2H)-one is used as a key intermediate in the synthesis of various cinnoline and phthalazine derivatives. These derivatives are important in the development of new pharmaceutical compounds.
Used as Phosphodiesterase 10 Inhibitors:
In the pharmaceutical industry, 6,7-Dimethoxyphthalazin-1(2H)-one is also utilized as a phosphodiesterase 10 (PDE10) inhibitor. PDE10 inhibitors are a class of compounds that have potential therapeutic applications in the treatment of various psychiatric and neurological disorders, such as schizophrenia and Huntington's disease.
Used in Chemical Synthesis:
6,7-Dimethoxyphthalazin-1(2H)-one serves as a valuable building block in the preparation of a wide range of chemical compounds, particularly those belonging to the cinnoline and phthalazine families. Its unique structure allows for further functionalization and modification, making it a versatile starting material for the synthesis of various organic compounds with potential applications in different industries.

Upstream product

• 490-63-1 2-formyl-4,5-dimethoxybenzoic acid 
• 40125-46-0 3-BROMO-5,6-DIMETHOXY-PHTHALIDE 
• 93-07-2 Veratric acid 
• 531-88-4 5,6-dimethoxyphthalide 

Downstream Products

• 70724-23-1 1-chloro-6,7-dimethoxyphthalazine 

Relevant academic research and scientific papers

Synthesis, biological evaluation and molecular modeling studies of phthalazin-1(2: H)-one derivatives as novel cholinesterase inhibitors

A new series of donepezil analogues based on the phthalazin-1(2H)-one scaffold was designed and synthesized with the aim of exploring its potential as human ChEIs. Biological results revealed that the structural modifications proposed significantly affected ChE inhibitory potency as well as selectivity for AChE/BuChE. Compound 1d showed promising in vitro inhibition of both enzymes in the μM range. However, most target compounds were significantly more active against AChE than BuChE, specifically 1f, 1h and 1j, with IC50 values in the low micromolar or submicromolar range, the most active compounds in the series. Docking simulations suggested that the most active compounds can recognize the donepezil binding site using a similar interactions network. These results allowed us to rationalize the observed structure-activity relationships. Moreover, the predicted physicochemical and ADME properties were also comparable to those of donepezil.

PHOSPHODIESTERASE 10 INHIBITORS

The present invention if directed to certain cinnoline compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10 enzyme, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

Cardiac stimulant 1-(3- or 4-substituted piperidino)phthalazines

1-(3- or 4-substituted piperidino)phthalazines of the formula wherein R is C1-6 alkyl; Y is a 3- or 4-position substituent and is -X-(CHR1)m-Z wherein R1 is hydrogen or C1-6 alkyl; m is 1 or 2; X is oxygen or a direct link provided that when m is 1, X is a direct link; and Z is -N(R2)COR3, -N(R2)COOR3, -N(R2)SO2R3, -N(R2)SO2NR4R5, -N(R2)SOR3, -N(R2)CONR4R5 or -OCONR4R5, wherein R2 and R5 are each independently hydrogen or C1-6 alkyl; R3 is C1-6 alkyl, phenethyl, benzyl, C3-7 cycloalkyl, phenyl or pyridyl; R4 is hydrogen or R3; provided that when X is a direct link, R3 or R4 is C3-7 cycloalkyl; the pharmaceutically acceptable acid addition salts thereof; processes for their preparation; and their use as cardiac stimulants and phosphodiesterase inhibitors

1-PIPERIDINOPHTHALAZINES AS CARDIAC STIMULANTS

A series of 1-piperidinophthalazine derivatives as phosphodiesterase inhibitors and cardiac stimulants